Skip to main content
. Author manuscript; available in PMC: 2014 Jan 25.
Published in final edited form as: Cancer Biol Ther. 2009 Mar 15;8(6):485–496. doi: 10.4161/cbt.8.6.7582

Figure 1.

Figure 1

Therapeutic strategies to block estrogen receptor function: Aromatase inhibitors like letrozole, anastrozole and exemestane inhibit the enzyme leading to decreased E2 levels. Selective ER downregulators (SERDs) like fulvestrant bind to ER and sequester it, thereby inhibiting ER-mediated gene transcripton and disrupting ER nuclear localization through the ubiquitin-proteosomal pathway.